Annual NMD4C Early-Career Awards Program Accepting Applications
We are excited to launch the second year of the NMD4C Early-Career Awards for 2024! This annual award program provides three awards, celebrating excellence and contribution to the neuromuscular field by early career neuromuscular investigators across both clinical and basic science streams.
These awards recognize outstanding achievement by early career neuromuscular researchers and clinicians, with recipients receiving a tangible accolade to bolster their academic CVs in pursuit of future academic appointments and grant applications. This award program is a part of the network’s broader strategy to provide support for Canadian early-career neuromuscular investigators.
The three categories included in the 2024 competition are:
- Early Career Biomedical Researcher of the Year
- Early Career Clinical Researcher of the Year
- Publication of the Year
Submit your nomination today – read the full guidelines and access the submission portal!
Deadline: January 15, 2024
Read next...
MDC and NMD4C Hiring Full-Time Clinical Trials and Community Practice Manager
Join our team of dedicated colleagues and volunteers in breaking down barriers for the neuromuscular community and help bring clinical trials to Canada!
NMD4C Pre-clinical Science Pillar Seeking Trainee Input
The NMD4C cell and animal-based research team is actively seeking the input of neuromuscular trainees to help inform our activities. If you are willing to participate in a committee that will meet periodically to share input on NMD4C cell and animal-based research activities, we want to hear from you!
NMD4C Investigators Dr Rashmi Kothary and Dr Natasha Chang Receive MDC Awards
We are excited to share that NMD4C investigators Dr Rashmi Kothary, and Dr Natasha Chang received the Dr George Karpati Award for Researcher of the Year and Rising Clinician/Researcher Award respectively from Muscular Dystrophy Canada
Vamorolone receives approval by the FDA in the US and positive opinion from CHMP in the EU for use in the treatment of Duchenne muscular dystrophy.
The FDA approved vamorolone on October 26, 2023 for the treatment of DMD in the US, while the CHMP has issued a positive opinion for vamorolone for the treatment of DMD in the EU.
Annual NMD4C Meeting Recap
Thank you to everyone who attended the Annual NMD4C Meeting on September 7th in Ottawa! We were thrilled to welcome 84 network investigators, general members, patient partners and trainees to outline the network activities for the next five years and kick off our new grant period. The meeting program consisted of presentations from task…
National Consensus Meeting to Decide Outcome Measures for Adults with SMA
On September 9th and 10th in Ottawa, Ontario, 14 adult SMA experts including, clinicians, allied health care providers, patient organization representatives, and the CNDR representatives gathered to reach an updated national consensus on outcome measures for adults with SMA.